Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

752
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
752
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.2K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.1K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.1K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

659
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
659
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.9K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.9K
Drug Therapy01:28

Drug Therapy

387
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
387

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A penicillin-binding protein inhibitor series to target drug-resistant Neisseria gonorrhoeae.

Nature microbiology·2026
Same author

Assessment of human exposures of cefepime-taniborbactam against cefepime-resistant Enterobacterales and <i>Pseudomonas aeruginosa</i> in a 7-day hollow fiber infection model.

Antimicrobial agents and chemotherapy·2025
Same author

A new class of penicillin-binding protein inhibitors to address drug-resistant <i>Neisseria gonorrhoeae</i>.

bioRxiv : the preprint server for biology·2025
Same author

In vivo pharmacokinetics and pharmacodynamics of ceftibuten/ledaborbactam, a novel oral β-lactam/β-lactamase inhibitor combination.

The Journal of antimicrobial chemotherapy·2022
Same author

Evaluation of the in vitro activity of WCK 5222 (cefepime/zidebactam) and currently available combination therapies against single- and double-carbapenemase producing Enterobacteriaceae: Expanding the zone of hope.

International journal of antimicrobial agents·2019
Same author

Comparative Evaluation of the <i>In Vitro</i> Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant <i>Pseudomonas aeruginosa</i>.

Antimicrobial agents and chemotherapy·2019

Related Experiment Video

Updated: Mar 22, 2026

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.6K

Bipolar depression: Managing patients with second generation antipsychotics.

Lindsay M Avery1, Shannon J Drayton2

  • 1South Carolina College of Pharmacy, Medical University of South Carolina, Charleston, SC, USA.

International Journal of Psychiatry in Medicine
|April 16, 2016
PubMed
Summary
This summary is machine-generated.

Bipolar depression treatment has limited FDA-approved options. This review examines clinical trials for olanzapine/fluoxetine, quetiapine, and lurasidone, aiding clinician selection of these second-generation antipsychotics.

Keywords:
bipolar disorder depressionlurasidoneolanzapine/fluoxetinequetiapinesecond generation antipsychotics

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.8K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

691

Related Experiment Videos

Last Updated: Mar 22, 2026

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.6K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.8K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

691

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Medicine

Background:

  • Bipolar affective disorder involves mood elevation and depression cycles.
  • Bipolar depression episodes are more prolonged than manic episodes.
  • Limited FDA-approved treatments exist specifically for bipolar depression.

Purpose of the Study:

  • To review clinical trials supporting FDA approval of second-generation antipsychotics for bipolar depression.
  • To provide guidance on pharmacologic treatment strategies for bipolar depression.
  • To detail monitoring, adverse effects, and counseling for these agents.

Main Methods:

  • Literature review of clinical trials.
  • Focus on FDA-approved agents for bipolar depression.
  • Analysis of treatment strategies, adverse effects, and patient counseling.

Main Results:

  • Olanzapine/fluoxetine, quetiapine (IR/XR), and lurasidone are FDA-approved for bipolar depression.
  • Clinical trial data supports the efficacy of these agents.
  • Key considerations for treatment selection are identified.

Conclusions:

  • Second-generation antipsychotics represent important pharmacologic options for bipolar depression.
  • Careful patient selection, monitoring, and counseling are crucial for effective treatment.
  • Further research may expand treatment options for bipolar depression.